Arbor Biotechnologies key facts
as of Oct 2026- Developer of genomic tools designed to improve human health and sustainability.
- Arbor Biotechnologies is valued at approximately $238.9M as of Oct 2026, set at its later-stage round, Oct 2025; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $304.5M across 2 recorded rounds; the latest was Later Stage VC ($215.0M) in Oct 2021.
- Notable investors include Temasek Holdings, Samsung Venture Investment, Alexandria Venture Investments, ARCH Venture Partners, Qatar Investment Authority — 31 tracked in total.
- Arbor Biotechnologies has filed 3 Form Ds with the SEC since 2017, most recently Nov 2021 ($215.0M sold to 37 investors).
- Status: Privately Held (backing).
Valued at $238.9M at its later-stage round, Oct 2025. Nothing has traded since.
- ·The complete investor list: 31 names
- ·Watch Arbor Biotechnologies: the Monday email on marks, rounds and moves
Arbor Biotechnologies funding rounds
2 roundsWho backs Arbor Biotechnologies
31+Arbor Biotechnologies valuation
Arbor Biotechnologies was valued at $239 million at its later-stage round in Oct 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Arbor Biotechnologies raised?
Arbor Biotechnologies has raised $305 million in total; 2 of its rounds are on record. The largest on record was a $215 million later-stage round in Oct 2021.
Arbor Biotechnologies has filed 3 Form Ds with the SEC since 2017, most recently in Nov 2021 ($215 million sold to 37 investors).
Arbor Biotechnologies investors
31 investors are on record for Arbor Biotechnologies, including Temasek Holdings, Samsung Venture Investment, Alexandria Venture Investments and ARCH Venture Partners. By type, the record holds 9 venture capital firms and 3 hedge funds. The later-stage round in Oct 2021 drew 37 investors.
About Arbor Biotechnologies
Developer of genomic tools designed to improve human health and sustainability. The company's tools use AI and machine learning to aggregate genomic sequence data to improve and streamline future cycles of curative treatments for previously incurable genetic diseases, enabling drug developers to replace whole genes and to precisely correct mutations to treat all patients with genetic diseases.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2016
- Employees
- 110
- Website
- arbor.bio/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.